CBDMD INC (YCBD) Stock Fundamental Analysis

USA • NYSE Arca • NYSEARCA:YCBD • US12482W4087

0.8003 USD
-0.05 (-6.1%)
Last: Feb 10, 2026, 10:59 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to YCBD. YCBD was compared to 191 industry peers in the Pharmaceuticals industry. YCBD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. YCBD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year YCBD has reported negative net income.
  • YCBD had a negative operating cash flow in the past year.
  • YCBD had negative earnings in each of the past 5 years.
  • In the past 5 years YCBD always reported negative operating cash flow.
YCBD Yearly Net Income VS EBIT VS OCF VS FCFYCBD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M

1.2 Ratios

  • The Return On Assets of YCBD (-41.99%) is comparable to the rest of the industry.
  • YCBD has a Return On Equity (-60.55%) which is in line with its industry peers.
Industry RankSector Rank
ROA -41.99%
ROE -60.55%
ROIC N/A
ROA(3y)-93.71%
ROA(5y)-96.7%
ROE(3y)-250.41%
ROE(5y)-202.47%
ROIC(3y)N/A
ROIC(5y)N/A
YCBD Yearly ROA, ROE, ROICYCBD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800

1.3 Margins

  • Looking at the Gross Margin, with a value of 62.37%, YCBD is in the better half of the industry, outperforming 71.73% of the companies in the same industry.
  • In the last couple of years the Gross Margin of YCBD has remained more or less at the same level.
  • YCBD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 62.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.39%
GM growth 5Y-0.19%
YCBD Yearly Profit, Operating, Gross MarginsYCBD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • YCBD does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, YCBD has more shares outstanding
  • YCBD has more shares outstanding than it did 5 years ago.
  • YCBD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
YCBD Yearly Shares OutstandingYCBD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M
YCBD Yearly Total Debt VS Total AssetsYCBD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -21.14, we must say that YCBD is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -21.14, YCBD is doing worse than 84.82% of the companies in the same industry.
  • There is no outstanding debt for YCBD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -21.14
ROIC/WACCN/A
WACC9.36%
YCBD Yearly LT Debt VS Equity VS FCFYCBD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M 60M 80M 100M

2.3 Liquidity

  • A Current Ratio of 2.05 indicates that YCBD has no problem at all paying its short term obligations.
  • YCBD has a Current ratio of 2.05. This is in the lower half of the industry: YCBD underperforms 60.73% of its industry peers.
  • YCBD has a Quick Ratio of 1.20. This is a normal value and indicates that YCBD is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.20, YCBD is doing worse than 73.82% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.05
Quick Ratio 1.2
YCBD Yearly Current Assets VS Current LiabilitesYCBD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 70.81% over the past year.
  • Looking at the last year, YCBD shows a decrease in Revenue. The Revenue has decreased by -1.50% in the last year.
  • The Revenue for YCBD have been decreasing by -14.45% on average. This is quite bad
EPS 1Y (TTM)70.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.13%
Revenue 1Y (TTM)-1.5%
Revenue growth 3Y-18.46%
Revenue growth 5Y-14.45%
Sales Q2Q%3.59%

3.2 Future

  • Based on estimates for the next years, YCBD will show a very strong growth in Earnings Per Share. The EPS will grow by 40.62% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y94.45%
EPS Next 2Y40.62%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year4.95%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
YCBD Yearly Revenue VS EstimatesYCBD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M
YCBD Yearly EPS VS EstimatesYCBD Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2023 2024 2025 2026 2027 0 -500 -1K -1.5K

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for YCBD. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for YCBD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
YCBD Price Earnings VS Forward Price EarningsYCBD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
YCBD Per share dataYCBD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

  • YCBD's earnings are expected to grow with 40.62% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.62%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • YCBD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CBDMD INC

NYSEARCA:YCBD (2/10/2026, 10:59:32 AM)

0.8003

-0.05 (-6.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)12-19
Earnings (Next)02-11
Inst Owners4.63%
Inst Owner Change4.53%
Ins Owners6.34%
Ins Owner Change30.68%
Market Cap7.13M
Revenue(TTM)19.19M
Net Income(TTM)-4.38M
Analysts82.86
Price Target2.04 (154.9%)
Short Float %10.7%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-533.75%
Min EPS beat(2)-929.41%
Max EPS beat(2)-138.09%
EPS beat(4)1
Avg EPS beat(4)-260.56%
Min EPS beat(4)-929.41%
Max EPS beat(4)41.71%
EPS beat(8)4
Avg EPS beat(8)-111.36%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-8.21%
Min Revenue beat(2)-14.83%
Max Revenue beat(2)-1.58%
Revenue beat(4)0
Avg Revenue beat(4)-7.3%
Min Revenue beat(4)-14.83%
Max Revenue beat(4)-1.58%
Revenue beat(8)1
Avg Revenue beat(8)-7.88%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20%
EPS NY rev (1m)-10%
EPS NY rev (3m)-10%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.21%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.37
P/FCF N/A
P/OCF N/A
P/B 0.99
P/tB 1.4
EV/EBITDA N/A
EPS(TTM)-4.04
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS2.15
BVpS0.81
TBVpS0.57
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -41.99%
ROE -60.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 62.37%
FCFM N/A
ROA(3y)-93.71%
ROA(5y)-96.7%
ROE(3y)-250.41%
ROE(5y)-202.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.39%
GM growth 5Y-0.19%
F-Score6
Asset Turnover1.84
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.36%
Cap/Sales 0.96%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.05
Quick Ratio 1.2
Altman-Z -21.14
F-Score6
WACC9.36%
ROIC/WACCN/A
Cap/Depr(3y)19.37%
Cap/Depr(5y)25.83%
Cap/Sales(3y)1.23%
Cap/Sales(5y)1.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.13%
EPS Next Y94.45%
EPS Next 2Y40.62%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-1.5%
Revenue growth 3Y-18.46%
Revenue growth 5Y-14.45%
Sales Q2Q%3.59%
Revenue Next Year4.95%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y34.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-154.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-311.68%
OCF growth 3YN/A
OCF growth 5YN/A

CBDMD INC / YCBD FAQ

What is the ChartMill fundamental rating of CBDMD INC (YCBD) stock?

ChartMill assigns a fundamental rating of 2 / 10 to YCBD.


What is the valuation status of CBDMD INC (YCBD) stock?

ChartMill assigns a valuation rating of 1 / 10 to CBDMD INC (YCBD). This can be considered as Overvalued.


How profitable is CBDMD INC (YCBD) stock?

CBDMD INC (YCBD) has a profitability rating of 1 / 10.


How sustainable is the dividend of CBDMD INC (YCBD) stock?

The dividend rating of CBDMD INC (YCBD) is 0 / 10 and the dividend payout ratio is 0%.